Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Novo Advances as Pfizer Drops Diabetics Deal: Copenhagen Mover

March 13 (Bloomberg) -- Novo Nordisk A/S, the world’s biggest insulin manufacturer, rose to a record-high in Copenhagen trading after Pfizer Inc. pulled out of a deal to sell diabetics products.

Novo rose as much as 1.1 percent to 812 kroner, an all-time high. The stock advanced 4.5 kroner, or 0.6 percent, to 807.50 kroner at 11:08 a.m. in the Danish capital.

Pfizer, the world’s biggest drugmaker, yesterday returned products rights to Biocon Ltd. Pfizer agreed in October 2010 to pay $200 million to the Bangalore-based company for four types of insulin, including a generic version of Novo’s NovoLog. Bagsvaerd, Denmark-based Novo generates about three-quarters of its annual revenue from sales from its diabetes care unit.

“We see this news as a clear positive for Novo,” Michael Novod, a Copenhagen-based analyst with Nordea Markets, said in a note today, repeating a strong buy recommendation on Novo shares. “We believe this highlights how difficult and challenging it is -- and will be -- to bring competitive biosimilar insulins to the U.S. and EU markets.”

To contact the reporter on this story: Christian Wienberg in Copenhagen at cwienberg@bloomberg.net

To contact the editor responsible for this story: Tasneem Brogger at tbrogger@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.